Guidelines for Managing imAEs
Last Reviewed March 2025
Disclaimer: This content is provided for educational purposes only and is not a substitute for independent clinical judgment. Always consult official product monographs and prescribing information before making treatment decisions. Do not delay or disregard professional medical advice because of information on this site. Use of this resource does not establish a physician–patient relationship. See the full disclaimer for details.
Community Immuno-Oncology Support Kit (CIOSK)
AIM With Immunotherapy Foundation - Immuno-Oncology Essentials (Canada)
NHS The Clatterbridge Cancer Centre Acute Immunotherapy Management Guidelines
2019 SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors
eviQ Management of Immune-Related Adverse Events
Society of Immunotherapy for Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-related Adverse Events
Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up
Management of Immunotherapy-Related Toxicities - NCCN Clinical Practice Guideline in Oncology
Alberta Health Services (AHS) Follow-up and Management of Checkpoint Inhibitor Related Toxicities in Cancer Patients Clinical Practice Guideline
BC Cancer Protocol Summary for Management of Immune-Mediated Adverse Reactions to Checkpoint Inhibitor Immunotherapy (SCIMMUNE)
Cancer Care Ontario Immune Checkpoint Inhibitor Side Effect ToolKit under “Provider Tools”
